Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report Journal Article
| Authors: | Taniguchi, H.; Takemoto, S.; Ozasa, M.; Honda, N.; Suyama, T.; Umeyama, Y.; Dotsu, Y.; Nakao, T.; Tomohito, K.; Gyotoku, H.; Yamaguchi, H.; Miyazaki, T.; Sakamoto, N.; Obase, Y.; Fukuda, M.; Fukuoka, J.; Mukae, H. |
| Article Title: | Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report |
| Abstract: | Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD-1) inhibitors have been reported to show antitumor effects in patients with high programmed death-ligand 1 (PD-L1) expressing SC, the efficacy of combined therapy with PD-1 inhibitor plus cytotoxic chemotherapy has not previously been clarified. We herein report a case of SC with low expression of PD-L1 and few pre-existing tumor-infiltrating lymphocytes which showed a remarkable response to pembrolizumab plus cytotoxic chemotherapy as first-line treatment. Our findings suggest that combined treatment might enhance the immunogenic response, even in immunologically ignored SCs. © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. |
| Keywords: | immunohistochemistry; cancer chemotherapy; clinical article; human tissue; protein expression; treatment response; aged; disease course; case report; advanced cancer; drug withdrawal; treatment duration; bone metastasis; cancer radiotherapy; cancer staging; cancer palliative therapy; cd8 antigen; t lymphocyte; tumor associated leukocyte; carboplatin; computer assisted tomography; multiple cycle treatment; tumor volume; docetaxel; pneumonia; lung tumor; prednisolone; immunotherapy; tumor cell; colitis; sarcomatoid carcinoma; thorax radiography; ossification; drug cytotoxicity; cd4 antigen; tumor growth; immunosuppressive treatment; lung biopsy; pemetrexed; treatment refusal; primary health care; programmed death 1 ligand 1; molecular pathology; pulmonary sarcomatoid carcinoma; ramucirumab; human; male; priority journal; article; pembrolizumab; programmed death-ligand 1; supportive care need |
| Journal Title: | Thoracic Cancer |
| Volume: | 12 |
| Issue: | 7 |
| ISSN: | 1759-7706 |
| Publisher: | Wiley-Blackwell Publishing Asia |
| Date Published: | 2021-04-01 |
| Start Page: | 1126 |
| End Page: | 1130 |
| Language: | English |
| DOI: | 10.1111/1759-7714.13890 |
| PUBMED: | 33605089 |
| PROVIDER: | scopus |
| PMCID: | PMC8017259 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 May 2021 -- Source: Scopus |
